High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
Authors
Keywords
Ovarian cancer, Growth factors, HB-EGF, NRG1β, IGF1, HGF, HGSOC, Metastasis, Tumor heterogeneity
Journal
Cancer Cell International
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-12-09
DOI
10.1186/s12935-015-0263-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models
- (2015) Kim Moran-Jones et al. Scientific Reports
- c-Met Overexpression Contributes to the Acquired Apoptotic Resistance of Nonadherent Ovarian Cancer Cells through a Cross Talk Mediated by Phosphatidylinositol 3-Kinase and Extracellular Signal-Regulated Kinase 1/2
- (2015) Maggie K.S. Tang et al. NEOPLASIA
- Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy
- (2014) Dan Tian et al. BMC Systems Biology
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Roles of VEGF-A signalling in development, regeneration, and tumours
- (2014) K. Matsumoto et al. JOURNAL OF BIOCHEMISTRY
- A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development
- (2014) Cheryl A Sherman-Baust et al. JOURNAL OF PATHOLOGY
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
- (2014) N. Jiang et al. MOLECULAR CANCER THERAPEUTICS
- Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
- (2013) Ruth Perets et al. CANCER CELL
- The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
- (2013) Jingcao Huang et al. Molecular Cancer
- Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment
- (2013) Y Kwon et al. ONCOGENE
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- In vitro cell migration and invasion assays
- (2012) Nina Kramer et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib
- (2011) Rexxi D. Prasasya et al. BIOTECHNOLOGY AND BIOENGINEERING
- Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality
- (2011) E. L. Goode et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis
- (2011) Guro Aune et al. GYNECOLOGIC ONCOLOGY
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
- (2010) Qing Sheng et al. CANCER CELL
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy
- (2010) Hiroshi Tsujioka et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor
- (2010) Christine Bolitho et al. ENDOCRINE-RELATED CANCER
- Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma☆
- (2010) Jesús Planagumà et al. HUMAN PATHOLOGY
- Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities
- (2010) Langland ONCOLOGY REPORTS
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- Role of Immunohistochemical Overexpression of Matrix Metalloproteinases MMP-2 and MMP-11 in the Prognosis of Death by Ovarian Cancer
- (2008) Martine Périgny et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- p70 S6 Kinase Promotes Epithelial to Mesenchymal Transition through Snail Induction in Ovarian Cancer Cells
- (2008) Y. L. Pon et al. CANCER RESEARCH
- Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression
- (2008) Laurie G. Hudson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: High level expression in clear cell carcinoma
- (2008) Brian P. Adley et al. GYNECOLOGIC ONCOLOGY
- The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin
- (2008) Hilary A. Kenny et al. JOURNAL OF CLINICAL INVESTIGATION
- Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
- (2008) Hiroshi Yagi et al. MOLECULAR CANCER THERAPEUTICS
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
- (2008) Martin Köbel et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started